The UK's Medicines and Healthcare products Regulatory Agency (MHRA) unveiled an aggressive agenda Nov. 23 for combating the market in counterfeit medicines and medical devices. The plan targets both regulated and unregulated supply chains.

The three-year anticounterfeit strategy calls for a complete assessment of current supply and distribution procedures in the UK and outlines the MHRA's approach to curbing the availability of counterfeit goods. Key to the plan is the launch of a dedicated, 24-hour hotline for reporting suspected counterfeit devices and drugs.

12 December 2007

Read the full story at fdanews.com.